Free Trial

Korro Bio (KRRO) Competitors

Korro Bio logo
$30.76 -3.63 (-10.56%)
Closing price 04:00 PM Eastern
Extended Trading
$30.82 +0.06 (+0.20%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KRRO vs. EVO, CVAC, COLL, PHVS, LENZ, ELVN, CALT, ZYME, STOK, and UPB

Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Evotec (EVO), CureVac (CVAC), Collegium Pharmaceutical (COLL), Pharvaris (PHVS), LENZ Therapeutics (LENZ), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Stoke Therapeutics (STOK), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Korro Bio vs. Its Competitors

Korro Bio (NASDAQ:KRRO) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Korro Bio and Korro Bio both had 3 articles in the media. Korro Bio's average media sentiment score of 1.77 beat Evotec's score of 0.92 indicating that Korro Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Korro Bio
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Evotec
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 4.6% of Korro Bio shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Korro Bio has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat Korro Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Korro BioN/A -61.51% -42.87%
Evotec -20.14%-16.94%-8.14%

Korro Bio currently has a consensus price target of $86.83, indicating a potential upside of 182.29%. Evotec has a consensus price target of $5.40, indicating a potential upside of 55.62%. Given Korro Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Korro Bio is more favorable than Evotec.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
Evotec
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Korro Bio has higher earnings, but lower revenue than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$2.27M127.24-$83.58M-$9.75-3.15
Evotec$862.40M1.43-$212.18MN/AN/A

Korro Bio has a beta of 2.66, indicating that its share price is 166% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Summary

Korro Bio beats Evotec on 11 of the 14 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRRO vs. The Competition

MetricKorro BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$288.84M$2.84B$5.79B$10.15B
Dividend YieldN/A56.65%5.69%4.61%
P/E Ratio-3.1523.5374.5925.92
Price / Sales127.24534.57449.5483.33
Price / CashN/A169.2537.0859.91
Price / Book1.805.3712.156.29
Net Income-$83.58M$32.95M$3.28B$270.85M
7 Day Performance-7.29%1.31%0.98%3.36%
1 Month Performance92.37%8.31%7.20%6.41%
1 Year Performance-23.94%0.29%63.06%28.26%

Korro Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRRO
Korro Bio
2.2297 of 5 stars
$30.76
-10.6%
$86.83
+182.3%
-17.1%$288.84M$2.27M-3.1570Positive News
EVO
Evotec
1.6822 of 5 stars
$3.49
+0.3%
$5.40
+54.7%
+1.5%$1.24B$862.40M0.004,827
CVAC
CureVac
3.9174 of 5 stars
$5.35
-0.7%
$6.83
+27.7%
+77.9%$1.21B$579.18M5.57880Short Interest ↑
COLL
Collegium Pharmaceutical
3.7126 of 5 stars
$37.75
-1.5%
$42.33
+12.1%
+7.9%$1.21B$631.45M36.30210Positive News
PHVS
Pharvaris
2.5212 of 5 stars
$21.83
-5.3%
$34.00
+55.7%
+12.0%$1.21BN/A-6.5030Positive News
LENZ
LENZ Therapeutics
1.6186 of 5 stars
$39.63
-5.6%
$49.60
+25.2%
+93.2%$1.20BN/A-20.86110Positive News
ELVN
Enliven Therapeutics
3.0118 of 5 stars
$20.02
-0.6%
$41.20
+105.8%
-13.7%$1.19BN/A-10.0150Insider Trade
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180News Coverage
ZYME
Zymeworks
2.3851 of 5 stars
$15.19
+0.9%
$21.43
+41.1%
+34.9%$1.14B$122.87M-10.13460Positive News
STOK
Stoke Therapeutics
3.969 of 5 stars
$21.99
+6.3%
$25.57
+16.3%
+62.0%$1.13B$36.56M25.87100Positive News
UPB
Upstream Bio
1.9734 of 5 stars
$18.73
-6.2%
$56.50
+201.7%
N/A$1.08B$2.37M0.0038Positive News

Related Companies and Tools


This page (NASDAQ:KRRO) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners